
{
  "Company Overview": {
    "Name": "Alkem Laboratories Ltd",
    "Sector": "Pharmaceuticals",
    "Industry": "Pharmaceuticals - Indian - Bulk Drugs & Formln",
    "Business Description": "Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.",
    "Market Position": "Fifth largest player in domestic formulation market with a market share of 3.9% as on March 31, 2022. Established leadership in acute therapy, with a strong market position in anti-infective, gastrointestinal, pain management, vitamins, minerals, and nutrient segments."
  },
  "Financial Metrics": {
    "Market Cap": "₹ 64,894 Cr.",
    "Current Price": "₹ 5,428",
    "High/Low": "₹ 6,440 / ₹ 4,407",
    "P/E Ratio": 29.9,
    "Book Value": "₹ 961",
    "Dividend Yield": "0.74 %",
    "ROCE": "19.7 %",
    "ROE": "19.6 %",
    "Face Value": "₹ 2.00",
    "Debt-to-Equity Ratio": null //Not explicitly provided in the HTML
  },
  "Performance Trends": {
    "Quarterly Results": {
      "Sales": [2800, 2619, 2484, 2576, 3079, 3041, 2903, 2968, 3440, 3324, 2936, 3032, 3415],
      "Expenses": [2176, 2121, 2147, 2373, 2625, 2442, 2549, 2579, 2693, 2616, 2534, 2423, 2662],
      "Operating Profit": [624, 498, 337, 203, 454, 599, 353, 389, 747, 708, 402, 609, 753],
      "OPM %": [22, 19, 14, 8, 15, 20, 12, 13, 22, 21, 14, 20, 22],
      "Other Income": [42, 54, 6, 51, 51, 45, -34, 66, 6, 42, 76, 120, 134],
      "Interest": [12, 11, 17, 26, 25, 27, 29, 30, 30, 25, 27, 29, 28],
      "Depreciation": [73, 77, 83, 76, 77, 78, 78, 72, 74, 70, 83, 80, 79],
      "Profit before tax": [582, 464, 243, 152, 402, 539, 212, 353, 648, 655, 367, 619, 780],
      "Tax %": [4, -15, 55, 13, 14, 15, 68, 18, 5, 8, 17, 11, 10],
      "Net Profit": [559, 533, 108, 131, 348, 460, 68, 288, 615, 604, 304, 550, 702],
      "EPS in Rs": [45.52, 43.96, 9.00, 10.68, 27.67, 38.03, 5.94, 23.98, 51.90, 49.76, 24.55, 45.60, 57.60]
    },
    "Annual Results": {
      "Sales": [2485, 3113, 3674, 4905, 5688, 6401, 7357, 8344, 8865, 10634, 11599, 12668, 12706],
      "Expenses": [2123, 2700, 3248, 4038, 4687, 5392, 6237, 6868, 6920, 8580, 9977, 10419, 10235],
      "Operating Profit": [362, 413, 427, 866, 1001, 1009, 1120, 1476, 1945, 2054, 1622, 2249, 2471],
      "OPM %": [15, 13, 12, 18, 18, 16, 15, 18, 22, 19, 14, 18, 19],
      "Other Income": [167, 162, 176, 227, 110, 115, 82, 102, 230, 146, 101, 186, 373],
      "Interest": [88, 93, 81, 71, 45, 55, 55, 65, 59, 52, 107, 112, 110],
      "Depreciation": [40, 52, 71, 93, 101, 143, 193, 253, 275, 304, 310, 299, 312],
      "Profit before tax": [402, 430, 451, 928, 965, 926, 955, 1260, 1842, 1844, 1305, 2023, 2422],
      "Tax %": [4, -1, 13, 19, 6, 31, 19, 9, 12, 9, 23, 10, 10],
      "Net Profit": [384, 435, 392, 752, 905, 638, 774, 1149, 1618, 1680, 1007, 1811, 2161],
      "EPS in Rs": [321.01, 364.10, 32.75, 62.02, 74.61, 52.77, 63.61, 94.26, 132.57, 137.63, 82.31, 150.19, 177.51]
    }
  },
  "Ratios": {
    "Growth Ratios": {
      "Compounded Sales Growth (10 Years)": "15%",
      "Compounded Sales Growth (5 Years)": "11%",
      "Compounded Sales Growth (3 Years)": "13%",
      "Compounded Sales Growth (TTM)": "3%",
      "Compounded Profit Growth (10 Years)": "16%",
      "Compounded Profit Growth (5 Years)": "20%",
      "Compounded Profit Growth (3 Years)": "7%",
      "Compounded Profit Growth (TTM)": "45%"
    },
    "Liquidity Ratios": null, //Not explicitly provided
    "Profitability Ratios": {
      "ROCE (10 Years)": "18%",
      "ROCE (5 Years)": "19%",
      "ROCE (3 Years)": "17%",
      "ROCE (Last Year)": "20%",
      "ROE (10 Years)": "18%",
      "ROE (5 Years)": "19%",
      "ROE (3 Years)": "17%",
      "ROE (Last Year)": "20%"
    },
    "Valuation Ratios": null, //Partially provided (P/E), others not explicitly stated.
    "Other Ratios": {
      "Debtor Days": [47, 43, 52, 42, 46, 62, 62, 72, 66, 65, 67, 65],
      "Inventory Days": [191, 163, 169, 169, 198, 221, 186, 198, 241, 262, 194, 197],
      "Days Payable": [99, 81, 101, 108, 122, 147, 119, 104, 112, 102, 87, 129],
      "Cash Conversion Cycle": [139, 126, 121, 103, 122, 135, 129, 167, 196, 225, 174, 132],
      "Working Capital Days": [96, 74, 60, 48, 65, 84, 88, 109, 117, 120, 107, 169]
    }
  },
  "Peer Comparison": {
    "Peers": [
      {"Name": "Sun Pharma.Inds.", "CMP": 1808.85, "P/E": 38.73, "Mar Cap": 434003.71, "Div Yld": 0.75, "NP Qtr": 3037.33, "Qtr Profit Var": 27.86, "Sales Qtr": 13291.39, "Qtr Sales Var": 9.01, "ROCE": 17.32},
      {"Name": "Cipla", "CMP": 1472.05, "P/E": 25.81, "Mar Cap": 118884.82, "Div Yld": 0.88, "NP Qtr": 1305.01, "Qtr Profit Var": 15.18, "Sales Qtr": 7051.02, "Qtr Sales Var": 5.58, "ROCE": 22.80},
      {"Name": "Mankind Pharma", "CMP": 2805.20, "P/E": 56.07, "Mar Cap": 112393.74, "Div Yld": 0.00, "NP Qtr": 634.43, "Qtr Profit Var": 34.84, "Sales Qtr": 2529.74, "Qtr Sales Var": 11.91, "ROCE": 24.57},
      {"Name": "Dr Reddy's Labs", "CMP": 1343.65, "P/E": 21.00, "Mar Cap": 112115.62, "Div Yld": 0.60, "NP Qtr": 1341.90, "Qtr Profit Var": -15.28, "Sales Qtr": 8038.20, "Qtr Sales Var": 16.45, "ROCE": 26.53},
      {"Name": "Lupin", "CMP": 2150.70, "P/E": 37.36, "Mar Cap": 98114.41, "Div Yld": 0.37, "NP Qtr": 859.48, "Qtr Profit Var": 74.12, "Sales Qtr": 5672.73, "Qtr Sales Var": 12.59, "ROCE": 15.72},
      {"Name": "Zydus Lifesci.", "CMP": 973.50, "P/E": 22.90, "Mar Cap": 97956.88, "Div Yld": 0.31, "NP Qtr": 920.20, "Qtr Profit Var": 13.62, "Sales Qtr": 5237.00, "Qtr Sales Var": 19.87, "ROCE": 22.34},
      {"Name": "Aurobindo Pharma", "CMP": 1241.70, "P/E": 19.96, "Mar Cap": 72756.00, "Div Yld": 0.36, "NP Qtr": 816.95, "Qtr Profit Var": 8.65, "Sales Qtr": 7796.07, "Qtr Sales Var": 7.99, "ROCE": 14.10},
      {"Name": "Alkem Lab", "CMP": 5427.50, "P/E": 29.86, "Mar Cap": 64893.90, "Div Yld": 0.74, "NP Qtr": 701.96, "Qtr Profit Var": 4.59, "Sales Qtr": 3414.67, "Qtr Sales Var": -0.74, "ROCE": 19.68}
    ],
    "Median": {
      "CMP": 78,
      "P/E": 33.34,
      "Mar Cap": 2869.55,
      "Div Yld": 0.05,
      "NP Qtr": 17.27,
      "Qtr Profit Var": 19.36,
      "Sales Qtr": 188.19,
      "Qtr Sales Var": 9.43,
      "ROCE": 14.1
    }
  },
  "Other Insights": {
    "Pros": "Company has been maintaining a healthy dividend payout of 37.4%",
    "Cons": [
      "Promoter holding has decreased over last quarter: -0.72%",
      "The company has delivered a poor sales growth of 11.5% over past five years.",
      "Tax rate seems low"
    ],
    "Disclaimer": "The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.",
    "Shareholding Pattern Notes": "* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards. Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes."
  },
  "Indices": [
    "Nifty LargeMidcap 250",
    "BSE 400 MidSmallCap Index",
    "BSE MidCap",
    "Nifty Pharma",
    "Nifty Midcap 100",
    "Nifty Midcap 50",
    "Nifty 200",
    "BSE Allcap",
    "Nifty Midcap 150",
    "Nifty 500 Multicap 50:25:25",
    "Nifty Healthcare Index",
    "BSE 250 LargeMidCap Index",
    "Nifty Total Market",
    "Nifty MidSmall Healthcare",
    "Nifty500 Multicap India Manufacturing 50:30:20",
    "BSE 500",
    "BSE 150 MidCap Index",
    "BSE Healthcare",
    "BSE 200",
    "BSE Dollex 200",
    "Nifty 500",
    "Nifty MidSmallcap 400"
  ]
}
